Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment
Authors
Keywords
-
Journal
Bone Research
Volume 5, Issue -, Pages 17021
Publisher
Springer Nature
Online
2017-10-11
DOI
10.1038/boneres.2017.21
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Change in Bone Mineral Density Is an Indicator of Treatment-Related Antifracture Effect in Routine Clinical Practice
- (2016) William D. Leslie et al. ANNALS OF INTERNAL MEDICINE
- Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis
- (2016) Kosuke Ebina et al. JOURNAL OF BONE AND MINERAL METABOLISM
- Clinical Implications of Hip Flexion in the Measurement of Spinal Bone Mineral Density
- (2016) Shota Ikegami et al. JOURNAL OF CLINICAL DENSITOMETRY
- Significant improvement of bone mineral density and bone turnover markers by denosumab therapy in bisphosphonate-unresponsive patients
- (2016) M. Kamimura et al. OSTEOPOROSIS INTERNATIONAL
- The skeletal muscle cross sectional area in long-term bisphosphonate users is smaller than that of bone mineral density-matched controls with increased serum pentosidine concentrations
- (2015) Shigeharu Uchiyama et al. BONE
- Parathyroid hormone: anabolic and catabolic actions on the skeleton
- (2015) Barbara C Silva et al. CURRENT OPINION IN PHARMACOLOGY
- Hypocalcaemia in patients with metastatic bone disease treated with denosumab
- (2015) Jean-Jacques Body et al. EUROPEAN JOURNAL OF CANCER
- Clinical Trials Express:Fracture Risk Reduction With Denosumab in Japanese Postmenopausal Women and Men With Osteoporosis: Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
- (2014) Toshitaka Nakamura et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT)
- (2014) T. Sugimoto et al. OSTEOPOROSIS INTERNATIONAL
- Identification of the Risk Factors Associated with Hypocalcemia Induced by Denosumab
- (2013) Naoto Okada et al. BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Vitamin D Status and Bone Mineral Density Changes During Alendronate Treatment in Postmenopausal Osteoporosis
- (2013) Christian Roux et al. CALCIFIED TISSUE INTERNATIONAL
- Denosumab in osteoporosis
- (2013) Dima L Diab et al. Expert Opinion On Drug Safety
- 25 hydroxyvitamin D serum levels influence adequate response to bisphosphonate treatment in postmenopausal osteoporosis
- (2012) Pilar Peris et al. BONE
- Effects of 25-Hydroxyvitamin D3Therapy on Bone Turnover Markers and PTH Levels in Postmenopausal Osteoporotic Women Treated with Alendronate
- (2012) José M. Olmos et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The impact of dietary calcium intake and vitamin D status on the effects of zoledronate
- (2012) S. Bourke et al. OSTEOPOROSIS INTERNATIONAL
- Vitamin D insufficiency does not affect response of bone mineral density to alendronate
- (2008) D. M. Antoniucci et al. OSTEOPOROSIS INTERNATIONAL
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started